Search for Structural Variants in Patients With DSD and Inconclusive Molecular Diagnosis (GENEXPLOR)
Primary Purpose
Disorder of Sex Development, 46,XY
Status
Not yet recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Identify structural variants by Optical Genome Mapping of DNA extracted from blood leukocytes
Sponsored by
About this trial
This is an interventional diagnostic trial for Disorder of Sex Development, 46,XY
Eligibility Criteria
Inclusion Criteria: homogeneous XY male karyotype. patient at least 6 months old severe to moderate DSD (Prader 1 to 5) for which the molecular diagnosis is inconclusive after a gene panel analysis. Exclusion Criteria: subject with a homogeneous or mosaic XX, or monosomal X karyotype. subject with an aneuploidy. subject with a conclusive molecular diagnosis explaining the observed DSD (i.e. carrier of a causal genotype already well characterized by functional studies)
Sites / Locations
- University Hospital Montpellier
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
patients with DSD and inconclusive molecular diagnosis
Arm Description
The one arm of the study will have a venous blood draw as part of the research. 1 EDTA tube of 5mL will be collected.
Outcomes
Primary Outcome Measures
Presence of constitutional structural variants detected by OGM
A structural variant, present at the constitutional state in leukocyte DNA, and considered as likely pathogenic or pathogenic, identified by OGM in at least one of the included patients.
Secondary Outcome Measures
Presence of mosaic structural variants detected by OGM
A structural variant, present at the mosaic state in leukocyte DNA (i.e. allelic imbalance less than 0.40), and considered as likely pathogenic or pathogenic, identified by OGM in at least one of the included patients.
Full Information
NCT ID
NCT05867979
First Posted
May 2, 2023
Last Updated
May 11, 2023
Sponsor
University Hospital, Montpellier
1. Study Identification
Unique Protocol Identification Number
NCT05867979
Brief Title
Search for Structural Variants in Patients With DSD and Inconclusive Molecular Diagnosis
Acronym
GENEXPLOR
Official Title
Search for Structural Variants in Patients With Disorders of Sex Development (DSD) and Inconclusive Molecular Diagnosis GENEXPLOR-DSD
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
June 15, 2023 (Anticipated)
Primary Completion Date
June 15, 2025 (Anticipated)
Study Completion Date
June 15, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Montpellier
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The goal of this clinical trial is to identify structural variants by Optical Genome Mapping (OGM) in the described participant population.
The main questions it aims to answer are:
Identify constitutional structural variants by OGM of DNA extracted from blood leukocytes of patients with DSD for which the molecular diagnosis is inconclusive.
Identify mosaic structural variants (present in a subpopulation of somatic cells only) by OGM of DNA extracted from blood leukocytes of patients with DSD for which the molecular diagnosis is inconclusive.
Compare the diagnostic yields of OGM and of Comparative Genome Hybridization Array (CGH array) methods.
Compare the diagnostic yields of the OGM and of Whole Genome Sequencing (National Sequencing Program), only if performed.
Participants will be required to:
a follow-up interview with a physician to review their own and family medical and surgical history, with a focusing on DSD.
An interview to assess their exposure to environmental pollutants during fetal life, using a validated questionnaire.
a blood test with a 5mL tube to perform optical genome mapping analysis.
Detailed Description
Patients with severe or moderate disorder of sex development (DSD) with a inconclusive molecular diagnosis will benefit from optical genome mapping analysis.
A venous blood sample on ethylenediaminetetraacetic acid (EDTA) tube (5mL) will be taken in order to extract the DNA that will be used for the optical genome mapping analysis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Disorder of Sex Development, 46,XY
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
This is a single-center molecular biology pilot study on a single group of 20 patients with a disorder of sex development and inconclusive molecular diagnosis.
The 20 blood samples from patients with severe or moderate DSD, with an inconclusive diagnosis will benefit from the Optical Genome Mapping.
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
patients with DSD and inconclusive molecular diagnosis
Arm Type
Experimental
Arm Description
The one arm of the study will have a venous blood draw as part of the research. 1 EDTA tube of 5mL will be collected.
Intervention Type
Diagnostic Test
Intervention Name(s)
Identify structural variants by Optical Genome Mapping of DNA extracted from blood leukocytes
Intervention Description
The one arm of the study will have a venous blood draw as part of the research. 1 EDTA tube of 5mL will be collected.
Primary Outcome Measure Information:
Title
Presence of constitutional structural variants detected by OGM
Description
A structural variant, present at the constitutional state in leukocyte DNA, and considered as likely pathogenic or pathogenic, identified by OGM in at least one of the included patients.
Time Frame
Day of inclusion
Secondary Outcome Measure Information:
Title
Presence of mosaic structural variants detected by OGM
Description
A structural variant, present at the mosaic state in leukocyte DNA (i.e. allelic imbalance less than 0.40), and considered as likely pathogenic or pathogenic, identified by OGM in at least one of the included patients.
Time Frame
Day of inclusion
10. Eligibility
Sex
Male
Gender Based
Yes
Gender Eligibility Description
XY male karyotype (i.e. on all leukocytes studied).
Minimum Age & Unit of Time
6 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
homogeneous XY male karyotype.
patient at least 6 months old
severe to moderate DSD (Prader 1 to 5) for which the molecular diagnosis is inconclusive after a gene panel analysis.
Exclusion Criteria:
subject with a homogeneous or mosaic XX, or monosomal X karyotype.
subject with an aneuploidy.
subject with a conclusive molecular diagnosis explaining the observed DSD (i.e. carrier of a causal genotype already well characterized by functional studies)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Françoise PARIS, MD PhD
Phone
+33615106371
Email
f-paris@chu-montpellier.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Anne BERGOUGNOUX, PharmD PhD
Phone
+33411759879
Email
anne.bergougnoux@inserm.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Françoise PARIS, MD PhD
Organizational Affiliation
University Hospital, Montpellier
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Montpellier
City
Montpellier
ZIP/Postal Code
34000
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anne BERGOUGNOUX, PharmD PhD
First Name & Middle Initial & Last Name & Degree
Nicolas KALFA, MD PhD
First Name & Middle Initial & Last Name & Degree
Jacques PUECHBERTY, MD PhD
First Name & Middle Initial & Last Name & Degree
Vincent GATINOIS, MD
First Name & Middle Initial & Last Name & Degree
Franck PELLESTOR, PUPH
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Search for Structural Variants in Patients With DSD and Inconclusive Molecular Diagnosis
We'll reach out to this number within 24 hrs